Fig. 4: TC2N damages EBP1-induced AKT phosphorylation in BC cells.
From: Identification of TC2N as a novel promising suppressor of PI3K-AKT signaling in breast cancer
a The protein level of TC2N, AKT and phosphorylated AKT were analyzed by WB after treatment with PI3K inhibitor in stable transfected BC cells. b The cell viability was measured by MTS assays after treatment with PI3K inhibitor in stable transfected BC cells. c The cell proliferation was measured by MTS assays after treatment with PI3K inhibitor in stable transfected BC cells. d The stable transfected BC cell lysates were subjected to IP using Flag antibody and then detected by WB using TC2N and EBP1 antibodies. e, f The stable transfected BC cell lysates were subjected to IP using AKT or EBP1 antibodies and then detected by WB using EBP1 or AKT antibodies. Normal IgG serves as a negative control. Whole-cell lysates were used as a positive control (Input). *P < 0.05; **P < 0.01
